Meningitis Vaccine Purification: Quality Control of Ultrafiltration Membrane Porosity - How to balance porosity, plugging, and lot-to-lot variability in filters. - BioPharm International


Meningitis Vaccine Purification: Quality Control of Ultrafiltration Membrane Porosity
How to balance porosity, plugging, and lot-to-lot variability in filters.

BioPharm International
Volume 23, Issue 8


The meningitis vaccine (NeisVac-C) comprises the de-O-acetylated form of group C meningococcal polysaccharide conjugated to tetanus toxoid. The polysaccharide purification process includes base treatment and subsequent diafiltration to remove hydrolyzed cell impurities. During development, a 100 kilodalton (kDa) nominal molecular weight cut-off (NMWCO) ultrafiltration membrane was used for the diafiltration, and process yields ranged from 87 to 135%. Unexpectedly, the yield from the first 12 production lots varied from 18 to 100%. Investigation revealed that ultrafiltration membrane porosity varied with different manufacturers' lots. The corrective action included changing from a 100 kDa to a 50 kDa NMWCO membrane; this change occurred just before license approval. To support the change, a process stream sample spiked with >200% of cell impurities was purified with the tightest 50 kDa membrane available. Even under this worst-case condition, the impurities were removed to meet the original specifications achieved by the 100 kDa membrane. The change was implemented and >100 lots have since been produced with satisfactory yield and purity.

NeisVac-C was introduced in the UK in the year 2000. Currently, it is licensed in 39 countries. The vaccine is used to prevent the invasive disease caused by Neisseria meningitidis serogroup C. The active ingredient of the vaccine is a polysaccharide–protein conjugate. Each dose of the vaccine contains 10 g of de-O-acetylated group C meningococcal polysaccharide (GCMP) conjugated to 10–20 g of tetanus toxoid protein (TT) and adsorbed to 0.5 mg of aluminum as aluminum hydroxide in saline.

NeisVac-C is the only meningitis conjugate vaccine on the market that uses the de-O-acetylated form of GCMP. Clinical data collected over the past 10 years demonstrate that the de-O-acetylated form is more immunogenic than the conjugate vaccine prepared from the O-acetylated form of GCMP.1

During polysaccharide purification development, we encountered a unique challenge with the ultrafiltration (UF) membrane used in the purification process. This article describes the problem and the solution.


The antigen component of the vaccine, de-O-acetylated GCMP, was purified from the culture supernatant of Neisseria meningitidis serogroup C, strain C11. The carrier protein, TT, was obtained from Statens Serum Institut, Denmark. The conjugation of GCMP to TT used reductive amination technology.2

The GCMP content was determined by a resorcinol-HCl method. This method measured GCMP monomer (sialic acid) by a colorimetric assay using N-acetyl neuraminic acid (sialic acid) as a standard.3

The protein impurity content in the process was determined by the Bradford method using BSA as a standard.4

The nucleic acid impurity content was determined by absorbance at 260 nm, assuming an absorbance of 1 (in a 1-cm wide cell) for 50 g/mL of nucleic acid.5

The molecular weight (MW) of GCMP 100 kDa retentate was determined by a laser-light-scattering method (Wyatt Technology Corp) after fractionation on an HPLC with Superose-6 column (GE Healthcare).6

blog comments powered by Disqus



Lundbeck CEO Resigns Due to Code of Conduct Breach
November 24, 2014
GPhA Issues Statement on Generic Drug Costs
November 20, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
Manufacturing Issues Crucial to Combating Ebola
November 20, 2014
FDA Requests Comments on Generic Drug Submission Criteria
November 20, 2014
Author Guidelines
Source: BioPharm International,
Click here